Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro
- PMID: 8144913
Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro
Abstract
The objectives of this study were to determine whether intensive immunotherapy with IL-2 results in detectable levels of circulating IL-1 and TNF antagonists and whether the levels achieved in vivo are sufficient to affect the generation of secondary proinflammatory cytokines such as IL-1 beta and TNF-alpha. We also sought to determine the extent to which endogenous TNF mediates the generation of an IL-1 antagonist by IL-2-activated PBMCs. In patients undergoing high dose IL-2 immunotherapy, plasma IL-1 receptor antagonist (IL-1ra) levels rose dramatically after the first IL-2 injection, reaching a plateau of 11.03 +/- 0.92 ng/ml within 4 h. TNF-soluble receptor p55 (TNFsRp55) was also detected in the plasma shortly after initiating treatment, and the levels progressively increased throughout the treatment course. PBMCs exposed to IL-2 expressed IL-1ra mRNA and secreted the IL-1ra protein, but neither PBMCs nor neutrophils shed TNFsRp55 in response to IL-2 or supernatants from IL-2-activated PBMCs. IL-1ra at concentrations achieved in the plasma during IL-2 immunotherapy (approximately 10 ng/ml) inhibited the in vitro production of IL-1 beta and TNF-alpha by IL-2-activated PBMCs by 65% and 30%, respectively. Although the monomeric receptor TNFsRp55 at concentrations achieved in the plasma had no effect on the in vitro production of IL-1ra, TNF-alpha, or IL-1 beta, the bivalent TNFsRp75-Fc chimera suppressed the generation of TNF and IL-1. IL-1ra synthesis was unaffected. These results suggest that the amount of IL-1ra generated in response to IL-2 is most likely sufficient to down-modulate the production of proinflammatory cytokines.
Similar articles
-
Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera.J Immunol. 1993 Sep 15;151(6):3299-307. J Immunol. 1993. PMID: 8397255
-
Analysis of the inflammatory cytokine network among TNF alpha, IL-1 beta, IL-1 receptor antagonist, and IL-8 in LPS-induced rabbit arthritis.Lab Invest. 1997 May;76(5):629-38. Lab Invest. 1997. PMID: 9166282
-
Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.Clin Exp Immunol. 1996 May;104 Suppl 1:10-20. Clin Exp Immunol. 1996. PMID: 8625537
-
The role of cytokines in osteoarthritis pathophysiology.Biorheology. 2002;39(1-2):237-46. Biorheology. 2002. PMID: 12082286 Review.
-
Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis.Kidney Int Suppl. 1992 Oct;38:S68-77. Kidney Int Suppl. 1992. PMID: 1328757 Review.
Cited by
-
Regulation of serum amyloid A protein expression during the acute-phase response.Biochem J. 1998 Sep 15;334 ( Pt 3)(Pt 3):489-503. doi: 10.1042/bj3340489. Biochem J. 1998. PMID: 9729453 Free PMC article. Review.
-
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.J Interferon Cytokine Res. 2014 May;34(5):376-84. doi: 10.1089/jir.2013.0010. Epub 2014 Jan 16. J Interferon Cytokine Res. 2014. PMID: 24433038 Free PMC article. Clinical Trial.
-
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Clin Drug Investig. 2017 Jul;37(7):587-624. doi: 10.1007/s40261-017-0519-y. Clin Drug Investig. 2017. PMID: 28361440 Review.
-
A Mixed-chimerism Protocol Utilizing Thymoglobulin and Belatacept Did Not Induce Lung Allograft Tolerance, Despite Previous Success in Renal Allotransplantation.Transplant Direct. 2021 May 25;7(6):e705. doi: 10.1097/TXD.0000000000001150. eCollection 2021 Jun. Transplant Direct. 2021. PMID: 34056080 Free PMC article.